RxSight, Inc.
NASDAQ•RXST
CEO: Dr. Ronald M. Kurtz M.D.
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2021-07-30
RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Contact Information
Market Cap
$321.12M
P/E (TTM)
-8.3
30
Dividend Yield
--
52W High
$27.13
52W Low
$6.32
52W Range
Rank59Top 87.6%
2.2
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 2.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025
Financial Dashboard
Q4 2025 Data
Revenue
$32.61M+0.00%
4-Quarter Trend
EPS
-$0.22+0.00%
4-Quarter Trend
FCF
$17.09M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Gross Margin Improvement Gross Profit reached $103.0M, up 4.1%; favorable LAL sales mix improved gross margin to 76.6%.
LAL Utilization Growth LAL sales increased 11,560 units year-over-year, driven by expanding installed base of 1,134 LDD units.
Strong Cash Position Total cash and short-term investments stand at $228.1M as of December 31, 2025, ensuring liquidity.
Adoption Milestones Reached Nearly 300,000 LALs implanted since inception through year-end 2025, validating commercial traction and adoption efforts.
Risk Factors
Sales Volume Decline Total Sales decreased 3.9% to $134.5M, primarily due to 47% drop in LDD unit sales for the year.
Widening Operating Loss Operating Loss widened 30.7% to $(48.2M) as SG&A expenses increased 11.1% to $112.7M.
Pending Litigation Exposure Facing securities class action and shareholder derivative lawsuits; adverse resolution could materially impact business.
Intense Market Competition Primary competitors (Alcon, J&J) control 75% of U.S. premium IOL market, posing intense competition risk.
Outlook
Focus on Revenue Growth Commercial realignment initiatives focus on renewed revenue growth via increased LAL utilization at existing practices.
Increased R&D Investment R&D spending increased 12.2% to $38.5M, targeting clinical outcomes, customer experience, and cost reduction.
Selective International Expansion Planning selective international expansion, holding regulatory approvals in Europe, Canada, Mexico, and Asia markets.
Capital Sufficiency Confirmed Expect current cash reserves of $228.1M to fund operations for at least the next 12 months.
Peer Comparison
Revenue (TTM)
$329.52M
$236.35M
$212.69M
Gross Margin (Latest Quarter)
91.5%
85.5%
80.6%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| BFLY | $949.78M | -12.3 | -35.3% | 6.9% |
| TCMD | $659.93M | 34.5 | 9.3% | 5.8% |
| SRDX | $614.51M | -34.8 | -15.6% | 19.2% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-4.9%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
25%
Cash Flow Needs Attention
Deep Research
Next earnings:May 12, 2026
EPS:-$0.30
|Revenue:$31.27M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data